Fig. 2: DSF has potential ameliorating effects on mice humanized with the fecal microbiota from NASH patients.

a HMA experimental design. WT mice were put on a course of intragastrically Abx administration for 1 week and then randomized into 4 groups (control, NASH, NASH + F and NASH + F + DSF) under a control diet, CDAHFD, CDAHFD and CDFHFD + DSF, respectively for 9 weeks. NASH + F and NASH + F + DSF mice were colonized with two NASH patients-derived fecal microbiota for 9 weeks to work in the contexts of the human microbiota. b–d Serum ALT and AST; hepatic TG. e Representative images of gross appearance of the liver histology (1 cm) and photomicrographs of fixed liver sections after staining with H&E (200 μm), ORO (200 μm), α-SMA antibody (200 μm), Masson (200 μm) and F4/80 antibody (50 μm). f Quantification of the liver index (%), NAS, fold change in ORO area, α-SMA-positive area (%), CVF (%) and F4/80-positive cells (%). a–f n = 5 individuals/group for the F4/80 IF staining; n = 9 individuals/group for other experiments. Each point represented an individual mouse. Differences in data were calculated by Kruskal–Wallis test or ordinary one-way ANOVA depending on the sample distribution type. Data were represented as mean ± SEM. Exact P values were all given. Data were pooled from three independent experiments. Abx antibiotic cocktail, α-SMA α-smooth muscle actin, CVF collagen volume fraction, DSF disulfiram, F fecal samples obtained from patients with NASH, FMT fecal microbiota transplantation, H&E hematoxylin and eosin, NAS NAFLD activity score, NASH nonalcoholic steatohepatitis, ORO oil red O, TG triglyceride. Source data are provided as a Source Data file.